LAUSR

Autologous stem cell transplantation (SCT) is an effective treatment for patients with relapsed and refractory follicular lymphoma (FL), but more than half patients experience relapse [1, 2]. Despite high transplant-related mortality, allogeneic SCT could be a curative treatment option [3]. However, only a limited number of studies have evaluated the role of allogeneic SCT for FL relapsing after autologous SCT [4, 5], and an appropriate transplantation procedure remains undetermined. Therefore, we used the Transplant Registry Unified Management Program database of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) and the Japanese Data Center for Hematopoietic Cell Transplantation [6] to retrospectively evaluate the outcome of allogeneic SCT for FL patients relapsing after autologous SCT. Members of the Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) are listed below Acknowledgements